Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Kisspeptin-10 and PT-141 — mechanism, side effects, legal status, and pricing.
Kisspeptin-10 (KP-10) is the 10-amino-acid C-terminal fragment of kisspeptin (the KISS1 gene product, also called metastin) that retains full biological activity. It is an investigational signaling peptide that sits at the top of the reproductive axis and is studied for fertility, hypogonadism, and as a diagnostic challenge. It is not FDA-approved.
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from melanotan II. It is FDA-approved as Vyleesi (2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women only. It acts centrally through the melanocortin system rather than on peripheral vasculature.
Kisspeptin-10
PT-141
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Kisspeptin-10
PT-141
COA corpus from Disclosed Labs — independently tested batches only.
Kisspeptin-10
50
COAs
99.6%
Avg purity
11
Labs
PT-141
83
COAs
99.7%
Avg purity
14
Labs
The foundational role of kisspeptin in reproduction was established by de Roux et al. (PNAS, 2003, PMID 12944565) and Seminara et al. (NEJM, 2003, PMID 14573733), who identified loss-of-function mutations in GPR54 causing hypogonadotropic hypogonadism. Dhillo et al. (JCEM, 2005) showed kisspeptin-54 stimulates LH, FSH, and testosterone in men; George et al. (JCEM, 2011, PMID 21632807) confirmed IV kisspeptin-10 boluses stimulate LH and increase pulse frequency in men. Young et al. (Neuroendocrinology, 2012, PMID 22377698) showed kisspeptin infusion restores pulsatile LH in patients with neurokinin B (TAC3/TACR3) signaling deficiencies. Abbara/Jayasena and colleagues (JCEM 2015, PMID 26192876; Hum Reprod 2017, PMID 28854728) demonstrated kisspeptin-54 can trigger oocyte maturation in IVF with very low OHSS rates. The kisspeptin receptor agonist MVT-602 has been in Phase 2 development for female HSDD. Grey-market SubQ use (~200 mcg 2x/week for libido or testosterone support) is not supported by controlled trials.
Key references
Bremelanotide received FDA approval in June 2019 (NDA 210557) based on the two Phase III RECONNECT trials reported by Kingsberg, Simon, Clayton, Portman et al. in Obstet Gynecol 2019 (PMID 31599840). Pooled 24-week data showed statistically significant increases in the Female Sexual Function Index desire domain and decreases in the Female Sexual Distress Scale compared with placebo, with long-term 52-week open-label safety reported in the companion paper (PMID 31599847). Earlier clinical programs in men with erectile dysfunction — including intranasal bremelanotide and the subcutaneous sildenafil-salvage study by Safarinejad & Hosseini (J Urol 2008, PMID 18206919) — showed modest efficacy but did not lead to approval in men. Safety monitoring shows transient SBP elevation (~6 mmHg) with reflex bradycardia resolving within ~12 hours; nausea (~40%) is the most common adverse event and typically diminishes with subsequent doses. Focal hyperpigmentation has been reported with repeated use, consistent with MC1R activity.
Kisspeptin-10 and PT-141 are both in the Hormone category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs